GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: GMI-1070 | PF-06460031 | PF-0646003102
Compound class:
Synthetic organic
Comment: Rivipansel is a synthetic glycomimetic molecule, rationally designed as a pan-selectin inhibitor [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Rivipansel is being assessed in a Phase 3 clinical trial as a potential therapy for vaso-occlusive crisis (VOC) in hospitalized patients with sickle cell disease. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
The selectins (E-selectin, L-selectin and P-selectin) are glycoprotein cell adhesion molecules implicated in inflammatory processes such as leukocyte adhesion which play a key role in VOC in sickle cell disease. Transgenic mice lacking both P- and E-selectins are protected from VOC [2], indicating the potential of these molecules for pharmaceutical inhibition. Phase II clinical trial with rivipansel in these patients sighnificantly decreased the time it took for the VOC to resolve. Rivipansel has been granted FDA orphan drug and fast track status for VOC, as the drug appears to benefit an as yet, unmet clinical need. |